TICKERNERD
Menu
STVNSTVNHealthcare · Medical Instruments & Supplies

STVN Stock Forecast: Stevanato Group SpA Price Predictions for 2026-2027

Last close, 14 Aug 2026
$21
−2.14% on the day

The 11 Wall Street analysts covering Stevanato Group SpA hold a median 12-month price target of $25 — +18.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 64 of 100 as at 15 Aug 2026 — in the upper half.

Market cap
$5.8B
Ticker Nerd rank
64 / 100
Median analyst target
$25
Analysts covering
11
Total return, dividends reinvested
1W
+3.9%
1M
+6.3%
YTD
+5.0%
1Y
−4.7%
From 52W high
−23.4%
From 52W low
+57.4%
$13
$28
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

STVN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Stevanato Group SpA on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
64 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
82
Volatility
75
Growth
70
Revisions
68
Quality
64
Issuance
50
Momentum
43
Accruals
42
Size
22

Value (82): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Accruals (42): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (22): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

STVN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on STVN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$15$20$25$30Oct 25Jan 26Apr 26Jul 26STVNHigh $32Median $25Low $20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says11 analysts
9 Buy2 Hold0 Sell
Low $20Median $25High $32

The green dot is the last close — the median target sits +18.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
16 June 2026TD CowenInitiatesBuy$25
2 June 2026Wolfe ResearchAssumesOutperform$21
6 Mar 2026Morgan StanleyMaintainsEqual-Weight—
5 Mar 2026CitigroupMaintainsBuy—
5 Mar 2026KeybancMaintainsOverweight—
2 Dec 2025Morgan StanleyMaintainsEqual-Weight—
11 Nov 2025Morgan StanleyMaintainsEqual-Weight—
7 Mar 2025UBSMaintainsNeutral—
13 Dec 2024B of A SecuritiesMaintainsBuy—
13 Dec 2024Wolfe ResearchInitiatesOutperform—
3 Dec 2024Morgan StanleyAssumesEqual-Weight$24 → $23
7 Aug 2024CitigroupMaintainsBuy—
15 July 2024Morgan StanleyMaintainsEqual-Weight—
22 Apr 2024Morgan StanleyMaintainsEqual-Weight—
25 Mar 2024Stephens & Co.ReiteratesOverweight—
1 Nov 2023JefferiesDowngradeHold—
1 Nov 2023Morgan StanleyMaintainsEqual-Weight—
26 Sept 2023Stephens & Co.InitiatesOverweight—
19 Sept 2023CJS SecuritiesInitiatesMarket Outperform—
30 Aug 2023KeybancMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. STVN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

STVN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−0.7%
Analysts raising
0
Analysts cutting
5
Fundamentals

Stevanato Group SpA (STVN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
38.3×

Cheaper than 21% of US stocks

Price / sales
4.7×

Cheaper than 27% of US stocks

Price / book
3.2×

Cheaper than 33% of US stocks

EV / EBITDA
20.9×

Cheaper than 16% of US stocks

Growth & margins
Revenue growth (YoY)
7.8%

Higher than 47% of US stocks

Earnings growth (YoY)
−22.7%

Higher than 19% of US stocks

Gross margin
28.7%

Higher than 33% of US stocks

Operating margin
17.2%

Higher than 75% of US stocks

Net margin
11.0%

Higher than 72% of US stocks

Returns & dividend
Return on equity
9.1%

Higher than 61% of US stocks

Return on assets
5.4%

Higher than 78% of US stocks

Dividend yield
1.2%

Higher than 28% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

STVN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
STVNStevanato Group SpA$5.8B
64
MMEDMiniMed Group, Inc.$5.7B
2
TFXTeleflex, Inc.$6.1B
82
BLCOBausch + Lomb Corp.$6.1B
86
MMSIMerit Medical Systems, Inc.$5.4B
90
NVSTEnvista Holdings Corp.$4.7B
99
ICUIICU Medical, Inc.$4.5B
96

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Stevanato Group SpA — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest STVN news & analysis

Stevanato Group Q2 Earnings Call Highlights

MarketBeat · 9 Aug 2026positive

Stevanato Group reported second-quarter 2026 revenue growth of 8%, driven by demand for higher-value drug containment and delivery products that lifted profitability. The company also updated its full-year outlook to reflect the divestiture of its California-based Balda C. Brewer subsidiary.

Why it matters — STVN watchers would care because the quarter shows growth and improved profitability from higher-value products, while the revised full-year outlook reflects a structural change from the Balda C. Brewer divestiture.

Is Stevanato (STVN) a Solid Growth Stock? 3 Reasons to Think "Yes"

Zacks Investment Research · 5 Aug 2026positive

Zacks Investment Research highlights Stevanato (STVN) as a stock positioned to outperform the market, citing its above-average growth in financials and outlining three reasons to view it as a solid growth stock.

Why it matters — The piece signals that analysts see Stevanato's financial growth as above-average, which is relevant for investors tracking the company's performance outlook.

Stevanato Group S.p.A. (STVN) Q2 2026 Earnings Call Transcript

Seeking Alpha · 4 Aug 2026neutral

Seeking Alpha published the transcript of Stevanato Group's Q2 2026 earnings call. The excerpt provides only the transcript's headline and does not include any details of the company's financial results or management remarks.

Why it matters — The transcript gives STVN watchers access to management's discussion of the company's second-quarter 2026 performance.

Stevanato Group (STVN) Q2 Earnings Top Estimates

Zacks Investment Research · 4 Aug 2026positive

Stevanato Group reported Q2 earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.15 per share and up from $0.12 per share a year ago.

Why it matters — The earnings beat and year-over-year increase signal stronger-than-expected quarterly performance for Stevanato Group.

Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026

Business Wire · 4 Aug 2026positive

Stevanato Group announced its financial results for the second quarter of fiscal 2026. Revenue rose 8% year over year to €302.0 million, high-value solutions accounted for 45% of total revenue, and the company reported an increase in gross profit margin.

Why it matters — A STVN watcher would care because the results show continued revenue growth and an improved gross margin in the company's drug containment and delivery business.

FAQ

Frequently asked questions about STVN stock

What is the STVN stock price forecast for 2026-2027?

The 11 Wall Street analysts covering Stevanato Group SpA have a median 12-month price target of $25, with estimates ranging from $20 to $32. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is STVN stock a buy right now?

Of the 11 analysts covering Stevanato Group SpA, 9 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Stevanato Group SpA 64 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank STVN?

As at 15 Aug 2026, Stevanato Group SpA ranks 64 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (82 of 100).

Will STVN stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +18.7% from the last close, and Ticker Nerd's factor model ranks Stevanato Group SpA 64 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the STVN stock forecast for 2030?

No analyst covering Stevanato Group SpA publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for STVN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $32 over the next 12 months.

How has STVN stock performed over the past year?

Stevanato Group SpA returned -4.7% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Stevanato Group SpA do?

Stevanato Group S.p.A. is a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries.

What is the latest news on STVN?

The most recent item we track (MarketBeat, 9 Aug 2026): "Stevanato Group Q2 Earnings Call Highlights". Stevanato Group reported second-quarter 2026 revenue growth of 8%, driven by demand for higher-value drug containment and delivery products that lifted profitability. The company also updated its full-year outlook to reflect the divestiture of its California-based Balda C. Brewer subsidiary.

Company

About Stevanato Group SpA.

Stevanato Group S.p.A. is a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries. The company offers an integrated portfolio of products, processes, and services that support customers across the entire drug life cycle, from development and clinical stages to commercial production. Its Biopharmaceutical and Diagnostic Solutions segment provides glass primary packaging such as vials, cartridges, syringes, and ampoules, alongside plastic components for drug delivery systems and in-vitro diagnostic consumables. The Engineering segment delivers specialized equipment including visual inspection systems, assembly lines, glass converting machinery, secondary packaging solutions, and analytical services to ensure product quality and regulatory compliance. Stevanato Group S.p.A. emphasizes technological innovation, manufacturing excellence, and a global footprint with production sites in multiple countries. Founded in 1949 and headquartered in Piombino Dese, Padua, Italy, it serves major players in the biopharmaceutical sector with end-to-end solutions for injectable drugs and diagnostic applications.

CEO Mr. Franco Stevanato · 5,521 employees · Italy · https://www.stevanatogroup.com